Globenewswireยท2025-09-17 20:15Company Overview - Vor Bio is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases [1][2] - The company is advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization [2][3] Clinical Study Details - Vor Bio announced 48-week clinical data from a Phase 3 study in China evaluating telitacicept in adults with generalized myasthenia gravis [1] - The study demonstrated a placebo-adjusted 4.83-point improvement in the Myasthenia Gravis Activities of Daily Living scale (MG-ADL) at 24 weeks, which is the primary endpoint of the trial [3] Product Information - Telitacicept selectively inhibits BLyS (BAFF) and APRIL, two cytokines essential for B cell and plasma cell survival, thereby reducing autoreactive B cells and autoantibody production [3] - Telitacicept is already approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) [4] Market Context - Generalized myasthenia gravis (gMG) is a rare, chronic autoimmune neuromuscular disorder affecting approximately 90,000 people in the United States, 140,000 in Europe, and 29,000 in Japan [5] - There is a significant unmet need for new therapies that provide durable efficacy and a favorable safety profile for gMG patients [5] Upcoming Presentation - The clinical data will be presented as an oral presentation at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting on October 29, 2025 [1][2]